Acurion Expands Leadership Team to Propel OncoGaze™ Towards Clinical Application

Acurion Strengthens Its Leadership and Advisory Team

Acurion, a pioneering company in precision oncology with a focus on AI-driven technologies, recently expanded its leadership team to bolster the advancement of its OncoGaze™ platform, which is on the trajectory of clinical utilization. This move comes in the wake of their successful seed financing round, in which they secured $4.3 million. The newly appointed team members bring a wealth of experience spanning various sectors of the healthcare and technology industries, aimed at enhancing Acurion's capabilities in science, regulation, and market deployment.

Among the new leadership is Mike Hoerres, who takes on the role of Chief Commercial Officer, leveraging his past experience at Cernostics, where he propelled the development and market introduction of innovative diagnostic technologies. Supporting him is Dr. David Schlessinger, appointed as Vice President of Product Development, who has previously illuminated the path for molecular diagnostics at prominent companies like Natera and Exact Sciences, thereby ensuring that biomarker technologies are effectively translated from lab to clinical settings.

The regulatory landscape is critical for any company that navigates the path towards clinical deployment, and Acurion welcomes Heather Jalisi as Vice President of Regulatory Affairs. With over twenty years in the field, Jalisi's expertise rooted in diagnostics and medical technologies is expected to streamline the regulatory processes crucial for safeguarding patient care.

Strategic partnerships are pivotal for innovation, and Acurion has placed Leandra Boysen in the role of Senior Director of Strategic Partnerships. Her extensive background in fostering alliances within the biotechnology sphere will be instrumental in driving synergistic initiatives that are vital for fostering growth and facilitating technology adoption in clinical practice. Furthermore, Rick Schmitt, as Vice President of Technology Operations, aims to streamline technology leadership across sectors, ensuring that Acurion remains at the forefront of technological advancements.

The academic realm is represented in Acurion's expanded team with the addition of Mariya Kazachkova, a freshly minted Ph.D. who brings her background in computational biology from the Broad Institute, reinforcing Acurion's capabilities in AI and machine learning applications.

Acurion’s board now also boasts distinguished figures such as Irwin Jacobs, co-founder of Qualcomm, and Dr. Eric Winer, Director of the Yale Cancer Center. Their invaluable insights and connections within the scientific community are set to enhance Acurion's strategic direction and reputation in the competitive oncology landscape.

Rick Fultz, Acurion's CEO, emphasized the importance of these appointments, stating, "These additions represent the level of expertise essential for developing clinically relevant AI tools that can significantly enhance patient care." The combination of deep experience across oncology, regulatory strategy, and technology provides a substantial foundation for Acurion as it gears up for its next formidable phase of growth.

Acurion’s current focus is on its OncoGaze™ platform, a revolutionary service that transforms conventional pathology images into actionable biomarker data, significantly enhancing the speed and efficiency of precision medicine. In an era where patients often face delays in accessing essential biomarker testing, Acurion aims to break down these barriers, advocating for timely and efficient cancer treatment interventions.

With a commitment to clinical collaborations and continuous expansion, Acurion is set to announce more partnerships in the near future, further solidifying its position as a leader in precision oncology. The optimistic trajectory suggests promising advancements in the landscape of cancer diagnostics, aligning with Acurion's vision to ensure every patient has access to cutting-edge, precision healthcare solutions.

In conclusion, Acurion's robust expansion of its leadership and advisory board symbolizes its commitment to innovating cancer care through AI technologies, setting a new standard for the industry. Stay tuned as Acurion continues its journey towards enhancing the landscape of personalized medicine in oncology.